Does Penile Traction Therapy Really Work?

Penile traction therapy produces statistically significant, measurable length gains of 1.3–2.3 cm (0.5–0.9 inches) over 3–6 months of daily use, confirmed across more than fifteen peer-reviewed clinical studies involving over 1,000 patients. The 2023 systematic review and meta-analysis by Almsaoud, Safar, and Alshahrani, published in Translational Andrology and Urology (PMID: 36895692), calculated a weighted mean length gain of 1.9 cm across twelve pooled studies. This body of evidence makes penile traction therapy the only non-surgical method for penis enlargement supported by this level of clinical validation.

Men asking whether penis stretchers really work, whether penile extenders really work, or whether devices like SizeGenetics or Jes-Extender deliver real results will find the answer in this same clinical evidence — these are all names for the same category of FDA-registered penile traction device manufactured by Danamedic ApS, and all operate on the same clinically validated traction mechanism. No other non-invasive approach — not pills, not pumps, not manual exercises — has a single randomised controlled trial demonstrating permanent tissue growth. Penile traction therapy does. The Toussi et al. randomised controlled trial (PMID: 34060339) demonstrated a 1.6 cm gain in the traction group versus just 0.3 cm in the control group (p<0.01), confirming that the gains are attributable to the device itself, not placebo or measurement variability. For men searching for proven male enlargement or penile traction therapy that actually works, the clinical record provides a clear, evidence-based answer.

Five landmark clinical studies define the evidence base for penile traction therapy, spanning more than fifteen years of independent research across institutions in North America, Europe, and the Middle East. Each study used calibrated traction devices — the same category of medical device sold today as a penis extender or penis stretcher — and each measured outcomes using standardised urological protocols. The results are consistent: penile traction therapy produces real, measurable tissue elongation. For a detailed guide on how to interpret these studies, see Understanding Penile Traction Studies.

Study Summary Table

For the full database of clinical studies on penile traction therapy, including additional studies on Peyronie's disease and post-surgical rehabilitation, see the complete clinical evidence page.

Penile traction device results across published clinical studies fall within a consistent range: 1.3–2.3 cm (0.5–0.9 inches) of gained length over 3–6 months of daily use at 4–6 hours per day. These are not marketing projections — these are measured outcomes from controlled clinical environments with standardised urological measurement protocols. Individual results depend on three primary variables: daily wear time, total treatment duration, and adherence to the prescribed traction protocol.

Adherence is the strongest predictor of outcomes. The Almsaoud meta-analysis reported an 82% adherence rate across pooled study populations, and the men who wore their devices consistently for the full prescribed duration achieved the upper end of the gain range. A penile traction device requires commitment — 4–6 hours of daily wear across 3–6 months — but the tissue growth it produces is permanent, driven by mechanotransduction — the process by which cells convert mechanical force into biological tissue growth — and cellular proliferation rather than temporary engorgement. For guidance on realistic timelines, see How Long to See Results from Penile Traction Therapy.

What "working" means in clinical terms: penile traction therapy produces measurable tissue elongation documented by calibrated rulers and standardised stretched penile length measurements. The gains are structural — new tissue formation via mechanotransduction in the tunica albuginea — not the temporary swelling produced by vacuum pumps. Available data suggests these gains persist after treatment cessation — Gontero et al. (PMID: 19138361) reported no further change in penile length in the six months following device discontinuation.

Honest limitations: No published clinical study has demonstrated consistent, statistically significant girth gains from penile traction therapy. Length gains are the documented, reproducible outcome. Additionally, results vary between individuals based on starting anatomy, tissue elasticity, age, and how strictly a man follows the daily wear protocol. Anyone promising guaranteed inches or overnight transformation is not reflecting the clinical evidence. For answers to the most common patient questions, consult the penile traction therapy FAQ.

Penile traction therapy is the only non-surgical penis enlargement method supported by meta-analytic evidence, randomised controlled trials, and prospective cohort studies published in peer-reviewed journals. Every other non-surgical approach — pills, pumps, manual exercises, and hanging weights — lacks this level of scientific validation. For men evaluating the most effective penis enlargement options, the evidence gap between traction therapy and every alternative is substantial.

Oral supplements and pills: No prescription or over-the-counter oral supplement has demonstrated permanent penile length gains in any published clinical trial. Zero randomised controlled trials. Zero meta-analyses. The marketing claims attached to herbal supplements are not supported by a single PubMed-indexed study showing structural tissue growth. These products may produce temporary vasodilatory effects, but they cannot trigger the mechanotransduction required for permanent cellular proliferation.

Vacuum erection devices (pumps): Vacuum pumps produce temporary engorgement by drawing blood into the erectile tissue. This is a legitimate medical tool for erectile dysfunction management, but the size increase is transient — it reverses within minutes of removing the device. No published study demonstrates permanent tissue growth from vacuum therapy alone.

Surgical augmentation: Penile lengthening surgery (ligamentolysis) can produce measurable gains but carries significant risks: infection, scarring, nerve damage, erectile dysfunction, and patient dissatisfaction rates as high as 30–50% in published series. Surgery also costs thousands of dollars and requires recovery time. Penile traction therapy achieves comparable length gains (1.3–2.3 cm) without surgical risks, anaesthesia, or recovery. For a deeper exploration of who benefits most from traction, see Who Should Use Penile Traction Therapy.

Hanging weights: Weight-based stretching applies uncontrolled, non-calibrated force to penile tissue. Unlike medical-grade penile traction devices that deliver precise, adjustable tension (measured in grams), hanging weights offer no tension regulation, no graduated force curves, and no safety mechanisms. The injury risk is substantially higher, and no published clinical study supports weight hanging as an effective or safe method.

Zero oral supplements, manual exercise programs, or vacuum pump protocols have produced a single peer-reviewed meta-analysis or randomised controlled trial demonstrating permanent penile length gains — yet hundreds of products make exactly that claim. Legitimate penile traction therapy is backed by named researchers, peer-reviewed journals, and verifiable PMIDs — the same evidence standards applied to any medical treatment. The challenge for consumers is distinguishing evidence-based claims from marketing fabrications in a market saturated with unsubstantiated promises. Knowing the difference protects both your health and your money.

Every clinical claim on this page links to its PubMed source. You can verify every study, every data point, and every researcher independently. This is how evidence-based medicine works — transparency, not marketing. For a detailed guide on reading and interpreting clinical studies on penile traction therapy, including how to assess study quality and statistical significance, see the full clinical evidence review. The safety and side effects page provides a complete analysis of adverse event data from published studies.

Danamedic ApS, founded in 1988 in Kongens Lyngby, Denmark, invented penile traction therapy in 1994 and filed the original patent in February 1995. Dr. Jørn Ege Siana, a board-certified plastic surgeon and medical advisor based in Copenhagen, co-invented the modern traction therapy mechanism that every device in this category is built upon. Over 32 years, Danamedic has sold more than 1,000,000 units across five brands: SizeGenetics, MaleEdge, Jes-Extender, ErectR, and Zestra.

Danamedic devices are FDA-registered Class II medical devices (FDA Registration #3005401991, product code LKY) and CE Marked under EU MDR. The majority of published clinical studies on penile traction therapy used Danamedic-engineered devices — the same calibrated traction mechanism delivering up to 3,200 grams of force across all five brands. When researchers at leading urology departments needed a traction device for clinical trials, they chose the category inventor's hardware.

This matters because clinical evidence is only as reliable as the device used to generate it. The penile traction device results published in journals such as the Journal of Urology, Journal of Sexual Medicine, and Translational Andrology and Urology were produced by the same calibrated traction mechanism manufactured by Danamedic. The engineering behind these devices — precise tension control, graduated force application, and medical-grade construction — is what enables the reproducible clinical outcomes documented across 15+ peer-reviewed studies. For guidance on selecting the right device, see Choosing the Right Penile Traction Device.

Penile traction therapy is part of a broader clinical evidence base spanning device selection, safety data, treatment protocols, and condition-specific applications. The following pages provide the next level of detail for each topic covered in this evidence review.